Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02273024
Other study ID # 14-7699
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2014
Est. completion date August 2019

Study information

Verified date November 2019
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators hypothesize that inactivity during the search for a donor may exacerbate current deconditioned states; subsequently, influencing risk factors for post-transplant complications that hinder the recovery phase.

This study is designed to investigate if exercise therapy administered prior to allogeneic hematologic stem cell transplantation (HSCT) can influence physical and psychological side-effects associated with HSCT. Approximately 6-weeks prior to HSCT, individuals will be randomized into either an exercise group or usual care group and followed until one year after HSCT.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date August 2019
Est. primary completion date August 2019
Accepts healthy volunteers No
Gender All
Age group 17 Years and older
Eligibility Inclusion Criteria:

- Medical indication: allogeneic stem cell transplantation at Princess Margaret Hospital

- must be ambulatory without need for human assistance at time of recruitment

- medically cleared to exercise by the transplant physician

- demonstrates willingness to attend supervised sessions

- sufficient in English to ensure safety of understanding prescribed exercise guidelines, or has access to an adequate non-familial interpreter

Exclusion Criteria:

- another active malignancy

- less than 4 weeks till the scheduled HSCT

- refusal to be randomized

- does not have the approval of their transplant physician

- severe or unstable neurological, cardiorespiratory, musculoskeletal disease or mental illness

Study Design


Related Conditions & MeSH terms

  • Allogeneic Stem Cell Transplantation

Intervention

Behavioral:
Exercise


Locations

Country Name City State
Canada Princess Margaret Hospital & Toronto Rehabilitation Institute Toronto Ontario

Sponsors (3)

Lead Sponsor Collaborator
University Health Network, Toronto Princess Margaret Hospital, Canada, Toronto Rehabilitation Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Adherence to exercise sessions Feasibility of an exercise intervention prior to HSCT till T100 One year
Primary Change in Physical Function Cardiopulmonary Capacity (VO2peak) Baseline, 1 week pre HSCT, T100, 1yr post HSCT
Secondary Change in Quality of Life European Organization for Research and Treatment of Cancer (EORTC) core 30-item questionnaire (QLQ-30) Baseline, 1 week pre HSCT, T100, 1yr post HSCT
Secondary Change in Symptoms Memorial Symptom Assessment Scale (MSAS) Baseline, 1 week pre HSCT, T100, 1yr post HSCT
Secondary Change in Anxiety The Generalized Anxiety Disorder (GAD7) Baseline, 1 week pre HSCT, T100, 1yr post HSCT
Secondary Change in Depression The Patient Health Questionnaire (PHQ-9), will be used as a clinically relevant measure to evaluate depression Baseline, 1 week pre HSCT, T100, 1yr post HSCT
Secondary Change in Fatigue Multidimensional Fatigue Inventory Baseline, 1 week pre HSCT, T100, 1yr post HSCT
Secondary Change in Treatment Side-effects Hospitalization (days till discharge and readmission rates), bone marrow engraftment (days), graft versus host disease incidence (acute & chronic), severity of diarrhea/ vomiting/ nausea, infections, steroid use, blood counts Baseline, 1 week pre HSCT, T100, 1yr post HSCT
Secondary Change in Strength upper body: grip strength; lower body: chair-stand test Baseline, 1 week pre HSCT, T100, 1yr post HSCT
Secondary Change in Six-minute walk test Baseline, 1 week pre HSCT, T100, 1yr post HSCT
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Terminated NCT01185223 - Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation Phase 3
Not yet recruiting NCT01212796 - Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH N/A
Terminated NCT00737113 - Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant Phase 1
Recruiting NCT06028828 - Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Not yet recruiting NCT03964922 - Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation N/A
Completed NCT03467074 - Role of Interferon-λ and Vaccine Response
Recruiting NCT06093334 - Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD N/A
Recruiting NCT03286530 - Ruxolitinib + Allogeneic Stem Cell Transplantation in AML Phase 2
Completed NCT01092026 - Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells N/A
Recruiting NCT01160952 - Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation Phase 2
Recruiting NCT00883714 - Exercise During the Allogeneic Stem Cell Transplantation Phase 3
Completed NCT04628338 - IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation Early Phase 1
Completed NCT06256341 - HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem.
Completed NCT05088941 - Impact of COVID-19 Pandemic on Allogeneic Stem Cell Transplantation Organization : a French Experience
Not yet recruiting NCT06453460 - Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla Phase 2
Recruiting NCT02533947 - Cognition in Allogeneic Stem Cell Transplanted Patients and Sports N/A
Completed NCT01560689 - Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation Phase 2
Not yet recruiting NCT06297629 - A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation Phase 2
Completed NCT01929980 - Bortezomib to Treat Significant Complication of HSCT Phase 2